+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years +
All Genders
ID07491523

Study Comparing Double Immunosuppressive Therapy With or Without Antifibrotic Treatment in Patients With Scleroderma-Related Lung Disease

Led by University of Patras · Updated on 2026-03-24

35

Participants Needed

1

Research Sites

34 weeks

Total Duration

AI-Summary

What This Trial Is About

Systemic sclerosis scleroderma is a rare autoimmune disease that mainly affects the skin but can also involve vital organs, causing fibrosis and vascular problems. This research focuses on patients with scleroderma who have lung involvement called interstitial lung disease ILD, which is a leading cause of death in this condition. The study aims to compare outcomes in patients receiving two different treatment approaches for this lung disease. Patients in this study are divided into two groups one group receives dual immunosuppressive therapy with mycophenolate mofetil MMF and rituximab RTX, while the other group receives the same dual immunosuppressive therapy combined with an antifibrotic drug such as nintedanib or pirfenidone. This study is retrospective and will analyze patient data over a two-year period from treatment start to compare these treatment regimens. Participants will have pulmonary function tests recorded at baseline, 6 months, and 12 months to assess lung function over time. Researchers will analyze lung function changes as the main outcome measure to understand the effects of these treatments on lung fibrosis progression. The study results may help improve management of scleroderma-related lung disease. The study is led by the University of Patras and includes patients followed at their Rheumatology Department.

CONDITIONS

Brief Title

Double Immunosuppression With or Without Anti-fibrotic in Scleroderma ILD

Research Team

S

Stamatis Nick Liossis C Professor, MD, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here